Healthy F-16 pilots show no evidence of exposure to tri-ortho-cresyl phosphate through the on-board oxygen generating system
-
Add time:07/23/2019 Source:sciencedirect.com
About 18% of fighter pilots complain of ill symptoms that begin during flight and persist for days. A possible source of toxicity is the air supplied through the on board oxygen generating system. The air passes through the jet engine before it is enriched for oxygen and breathed through an oxygen mask. While in the jet engine, the air can become contaminated with jet engine lubricating oil. A potentially toxic component in jet engine oil is tri-ortho-cresyl phosphate (TOCP), which is metabolically activated to the highly reactive cresyl saligenin phosphate. The cresyl saligenin phosphate reacts with butyrylcholinesterase (BChE) to make a covalent adduct on serine 198. The purpose of this work was to determine whether the blood of healthy, active-duty F-16 pilots has measurable levels of the cresyl phosphate adduct. BChE was immunopurified from 0.5 ml plasma by binding to immobilized monoclonal mAb2. BChE protein was released with acetic acid, digested with pepsin and analyzed by LC–MS/MS on the 5600 Triple TOF mass spectrometer. Positive controls for quantifying the limit of detection were plasma samples containing known amounts of cresyl saligenin phosphate treated plasma. The cresyl phosphate adduct eluted at 31.3 min with an observed parent ion mass of 966.4 m/z and characteristic daughter ions 778.3, 673.3, and 602.3 m/z. Control experiments demonstrated that as little as 0.1% of the 1–2 μg BChE recovered from 0.5 ml plasma could be detected as the cresyl phosphate adduct on peptide FGES198AGAAS. Mass spectrometry analysis of plasma from fifteen healthy F-16 pilots showed that none had evidence of exposure to TOCP. It was concluded that the on-board oxygen generating system, when operating properly, did not deliver tri-ortho-cresyl phosphate in the oxygen supply.
We also recommend Trading Suppliers and Manufacturers of ortho-Phosphate (cas 11-36-9). Pls Click Website Link as below: cas 11-36-9 suppliers
Prev:Palladium(II)-catalyzed ortho-arylation via phosphate-group-directed C–H activation
Next:Activation of mitochondria-mediated apoptotic pathway in tri-ortho-cresyl phosphate-induced delayed neuropathy) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Involvement of neuropathy target esterase in tri-ortho-cresyl phosphate-induced testicular spermatogenesis failure and growth inhibition of spermatogonial stem cells in mice07/28/2019
- Changes in beclin-1 and micro-calpain expression in tri-ortho-cresyl phosphate-induced delayed neuropathy07/27/2019
- Synthesis and evaluation of anticancer activity of BOC26P, an ortho-aryl chalcone sodium phosphate as water-soluble prodrugs in vitro and in vivo07/26/2019
- Dispersive micro-solid phase extraction of ortho-Phosphate (cas 11-36-9) ions onto magnetite nanoparticles and determination as its molybdenum blue complex07/25/2019
- Activation of mitochondria-mediated apoptotic pathway in tri-ortho-cresyl phosphate-induced delayed neuropathy07/24/2019
- Palladium(II)-catalyzed ortho-arylation via phosphate-group-directed C–H activation07/22/2019
- Involvement of autophagy in tri-ortho-cresyl phosphate- induced delayed neuropathy in hens07/20/2019
- Tri-ortho-cresyl phosphate (TOCP) induced ovarian failure in mice is related to the Hippo signaling pathway disruption07/21/2019
- Activation of PINK1-Parkin-dependent mitophagy in Tri-ortho-cresyl phosphate-treated Neuro2a cells07/19/2019


